STOCK Rag2tm1Fwa B2mtm1Unc H2-Ab1tm1Doi Il2rgtm1Sug Tg(HLA-A/H2-D/B2M)1Bpe Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dma/Orl

Status

Available to order

EMMA IDEM:06326
International strain nameSTOCK Rag2tm1Fwa B2mtm1Unc H2-Ab1tm1Doi Il2rgtm1Sug Tg(HLA-A/H2-D/B2M)1Bpe Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dma/Orl
Alternative nameSURE-L1/Rag2°/°GammaC°/°
Strain typeTransgenic Strains
Allele/Transgene symbolTg(HLA-DRA*0101,HLA-DRB1*0101)1Dma
Gene/Transgene symbolTg(HLA-DRA*0101,HLA-DRB1*0101)1Dma

Information from provider

ProviderYu Chun LONE
Provider affiliationINSERM U1014
Genetic informationSure-L1 (EM:01783) line was additionally knocked-out in Rag2 and Il2rg (gammaC) genes.
Phenotypic informationHLA-A2+/+; DR1+/+; IAbeta°/°; Rag2°/°; GammaC°/°
References
  • A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice.;Pajot Anthony, Michel Marie-Louise, Fazilleau Nicolas, Pancré Véronique, Auriault Claude, Ojcius David M, Lemonnier François A, Lone Yu-Chun, ;2004;European journal of immunology;34;3060-9; 15468058
Homozygous fertileyes
Homozygous viableyes
Homozygous matings requiredyes
Immunocompromisedyes

Information from EMMA

Archiving centreInstitut de Transgenose, INTRAGENE, Orléans, France
Animals used for archivinghomozygous C57BL/6J, homozygous C57BL/6J
Breeding at archiving centreAnimals are transgenic for Tg(HLA-A/H2-D/B2M)1Bpe (HLA-A2) and Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dma (DR1), homozygous knock-out for H2-Ab1 (IAbeta), Rag2 and Il2rg (GammaC), heterozygous knock-out for B2m (Beta2m).
Stage of embryos2-cell

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

MGI phenotypes (allele matching)
  • decreased level of surface class I molecules / MGI
  • decreased CD8-positive, alpha-beta T cell number / MGI
  • decreased IgG level / MGI
  • abnormal pancreas morphology / MGI
  • decreased susceptibility to bacterial infection / MGI
  • increased IgM level / MGI
  • decreased susceptibility to autoimmune diabetes / MGI
  • decreased circulating serum albumin level / MGI
  • increased T-helper 1 cell number / MGI
  • abnormal interleukin level / MGI
  • abnormal tumor necrosis factor level / MGI
  • increased susceptibility to infection induced morbidity/mortality / MGI
  • absent CD8-positive, alpha-beta T cells / MGI
  • abnormal pancreatic beta cell morphology / MGI
  • abnormal T cell number / MGI
  • insulitis / MGI
  • abnormal neuron proliferation / MGI
  • abnormal immune system morphology / MGI
  • abnormal spleen morphology / MGI
  • abnormal immune system cell morphology / MGI
  • postnatal growth retardation / MGI
  • abnormal immune system physiology / MGI
  • reduced fertility / MGI
  • abnormal spleen periarteriolar lymphoid sheath morphology / MGI
  • abnormal spleen marginal zone morphology / MGI
  • abnormal CD4-positive, alpha beta T cell morphology / MGI
  • abnormal T cell physiology / MGI
  • abnormal B cell physiology / MGI
  • abnormal immune system organ morphology / MGI
  • abnormal cytokine secretion / MGI
  • decreased susceptibility to parasitic infection / MGI
  • increased susceptibility to parasitic infection / MGI
  • abnormal CD4-positive, alpha-beta T cell physiology / MGI
  • increased CD4-positive, alpha beta T cell number / MGI
  • decreased CD4-positive, alpha beta T cell number / MGI
  • increased CD8-positive, alpha-beta T cell number / MGI
  • abnormal spleen B cell follicle morphology / MGI
  • absent spleen germinal center / MGI
  • decreased IgG1 level / MGI
  • abnormal lymph node cell ratio / MGI
  • abnormal estrous cycle / MGI
  • abnormal maternal decidual layer morphology / MGI
  • reproductive system phenotype / MGI
  • absent uterine NK cells / MGI
  • prolonged estrous cycle / MGI
  • prolonged diestrus / MGI
  • prolonged metestrus / MGI
  • abnormal placenta metrial gland morphology / MGI
  • abnormal decidua basalis morphology / MGI
  • increased granulocyte number / MGI
  • spleen hypoplasia / MGI
  • decreased body size / MGI
  • arrested B cell differentiation / MGI
  • decreased IgM level / MGI
  • thymus hypoplasia / MGI
  • arrested T cell differentiation / MGI
  • increased susceptibility to infection / MGI
  • abnormal effector T cell morphology / MGI
  • increased natural killer cell mediated cytotoxicity / MGI
  • decreased double-positive T cell number / MGI
  • increased macrophage cell number / MGI
  • lymph node hypoplasia / MGI
  • absent mature B cells / MGI
  • abnormal T cell receptor V(D)J recombination / MGI
  • abnormal immunoglobulin V(D)J recombination / MGI
  • decreased thymocyte number / MGI
  • lung inflammation / MGI
  • increased susceptibility to bacterial infection / MGI
  • abnormal macrophage physiology / MGI
  • colitis / MGI
  • abnormal T-helper 1 physiology / MGI
  • abnormal response to transplant / MGI
  • abnormal interferon secretion / MGI
  • abnormal chemokine secretion / MGI
  • decreased susceptibility to bacterial infection induced morbidity/mortality / MGI
  • abnormal intestinal mucosa morphology / MGI
  • abnormal B cell morphology / MGI
  • decreased double-negative T cell number / MGI
  • increased double-negative T cell number / MGI
  • decreased susceptibility to type IV hypersensitivity reaction / MGI
  • abnormal stomach mucosa morphology / MGI
  • abnormal intestinal epithelium morphology / MGI
  • abnormal B cell number / MGI
  • decreased pre-B cell number / MGI
  • decreased mature B cell number / MGI
  • increased immature B cell number / MGI
  • decreased immature B cell number / MGI
  • abnormal gamma-delta T cell differentiation / MGI

Literature references

  • A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice.;Pajot Anthony, Michel Marie-Louise, Fazilleau Nicolas, Pancré Véronique, Auriault Claude, Ojcius David M, Lemonnier François A, Lone Yu-Chun, ;2004;European journal of immunology;34;3060-9; 15468058

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).